KR100422286B1 - Ｃｅｔｐ억제제로서의 4-아미노치환-2-치환-1,2,3,4-테트라히드로퀴놀린 - Google Patents

Ｃｅｔｐ억제제로서의 4-아미노치환-2-치환-1,2,3,4-테트라히드로퀴놀린 Download PDF

Info

Publication number
KR100422286B1
KR100422286B1 KR10-2001-7003416A KR20017003416A KR100422286B1 KR 100422286 B1 KR100422286 B1 KR 100422286B1 KR 20017003416 A KR20017003416 A KR 20017003416A KR 100422286 B1 KR100422286 B1 KR 100422286B1
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
bis
quinoline
dihydro
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2001-7003416A
Other languages
English (en)
Korean (ko)
Other versions
KR20010085814A (ko
Inventor
마이클 폴 데니노
죠지 텟테 매그너스-아리테이
로저 벤자민 러거리
로날드 써레 웨스터
Original Assignee
화이자 프로덕츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인크. filed Critical 화이자 프로덕츠 인크.
Publication of KR20010085814A publication Critical patent/KR20010085814A/ko
Application granted granted Critical
Publication of KR100422286B1 publication Critical patent/KR100422286B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR10-2001-7003416A 1998-09-17 1999-09-10 Ｃｅｔｐ억제제로서의 4-아미노치환-2-치환-1,2,3,4-테트라히드로퀴놀린 Expired - Fee Related KR100422286B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10092798P 1998-09-17 1998-09-17
US60/100,927 2008-09-29

Publications (2)

Publication Number Publication Date
KR20010085814A KR20010085814A (ko) 2001-09-07
KR100422286B1 true KR100422286B1 (ko) 2004-03-11

Family

ID=22282246

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7003416A Expired - Fee Related KR100422286B1 (ko) 1998-09-17 1999-09-10 Ｃｅｔｐ억제제로서의 4-아미노치환-2-치환-1,2,3,4-테트라히드로퀴놀린

Country Status (50)

Country Link
US (2) US6140343A (cg-RX-API-DMAC7.html)
EP (1) EP1114032B1 (cg-RX-API-DMAC7.html)
JP (1) JP3561474B2 (cg-RX-API-DMAC7.html)
KR (1) KR100422286B1 (cg-RX-API-DMAC7.html)
CN (2) CN1318057A (cg-RX-API-DMAC7.html)
AP (1) AP1345A (cg-RX-API-DMAC7.html)
AR (1) AR030523A1 (cg-RX-API-DMAC7.html)
AT (1) ATE268324T1 (cg-RX-API-DMAC7.html)
AU (1) AU747715B2 (cg-RX-API-DMAC7.html)
BG (1) BG65101B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913855A (cg-RX-API-DMAC7.html)
CA (1) CA2344248C (cg-RX-API-DMAC7.html)
CO (1) CO5290250A1 (cg-RX-API-DMAC7.html)
CR (1) CR6306A (cg-RX-API-DMAC7.html)
CU (1) CU23053A3 (cg-RX-API-DMAC7.html)
CZ (1) CZ2001954A3 (cg-RX-API-DMAC7.html)
DE (1) DE69917790T2 (cg-RX-API-DMAC7.html)
DK (1) DK1114032T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2891A1 (cg-RX-API-DMAC7.html)
EA (1) EA005761B1 (cg-RX-API-DMAC7.html)
EE (1) EE200100167A (cg-RX-API-DMAC7.html)
ES (1) ES2221420T3 (cg-RX-API-DMAC7.html)
GC (1) GC0000108A (cg-RX-API-DMAC7.html)
GE (1) GEP20032973B (cg-RX-API-DMAC7.html)
GT (1) GT199900147A (cg-RX-API-DMAC7.html)
HK (1) HK1039938A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010200B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0103512A3 (cg-RX-API-DMAC7.html)
ID (1) ID27838A (cg-RX-API-DMAC7.html)
IL (1) IL141388A0 (cg-RX-API-DMAC7.html)
IS (1) IS2278B (cg-RX-API-DMAC7.html)
MA (1) MA26689A1 (cg-RX-API-DMAC7.html)
MY (1) MY121405A (cg-RX-API-DMAC7.html)
NO (1) NO319781B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ509837A (cg-RX-API-DMAC7.html)
OA (1) OA11651A (cg-RX-API-DMAC7.html)
PA (1) PA8481201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20001054A1 (cg-RX-API-DMAC7.html)
PL (1) PL198124B1 (cg-RX-API-DMAC7.html)
PT (1) PT1114032E (cg-RX-API-DMAC7.html)
SI (1) SI1114032T1 (cg-RX-API-DMAC7.html)
SK (1) SK3532001A3 (cg-RX-API-DMAC7.html)
SV (1) SV1999000150A (cg-RX-API-DMAC7.html)
TN (1) TNSN99170A1 (cg-RX-API-DMAC7.html)
TR (1) TR200100780T2 (cg-RX-API-DMAC7.html)
TW (1) TW502022B (cg-RX-API-DMAC7.html)
UA (1) UA70960C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000017165A1 (cg-RX-API-DMAC7.html)
YU (1) YU18101A (cg-RX-API-DMAC7.html)
ZA (1) ZA200101745B (cg-RX-API-DMAC7.html)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003269327A1 (en) * 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
JPWO2004052863A1 (ja) * 2002-12-06 2006-04-13 協和醗酵工業株式会社 抗炎症剤
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
WO2004072042A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
JP2006521344A (ja) * 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
KR100859223B1 (ko) * 2004-06-24 2008-09-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2008510835A (ja) * 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
AU2006265975B2 (en) * 2005-07-01 2011-12-15 Merck Sharp & Dohme Corp. Process for synthesizing a CETP inhibitor
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP4960355B2 (ja) * 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー／エス ウレア型グルコキナーゼ活性化剤
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
GB0615670D0 (en) * 2006-08-07 2006-09-13 Syngenta Participations Ag Chemical compounds
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
AU2008204530B2 (en) * 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
CN101220021B (zh) * 2007-01-12 2010-12-08 上海医药工业研究院 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CA2683534C (en) 2007-04-13 2015-02-24 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
CN101795691A (zh) * 2007-07-02 2010-08-04 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US9052326B2 (en) 2011-01-26 2015-06-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Method for assessing a subject's risk of having a cardiovascular disease
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (cg-RX-API-DMAC7.html) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
MX376135B (es) * 2014-08-28 2025-03-04 Newamsterdam Pharma B V Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
BR112023000808A2 (pt) 2020-07-29 2023-02-07 Amryt Pharmaceuticals Inc Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818448A1 (de) * 1996-07-08 1998-01-14 Bayer Ag Cycloalkano-pyridine als CETP-Inhibitoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818448A1 (de) * 1996-07-08 1998-01-14 Bayer Ag Cycloalkano-pyridine als CETP-Inhibitoren

Also Published As

Publication number Publication date
OA11651A (en) 2004-12-07
IS2278B (is) 2007-09-15
SI1114032T1 (cg-RX-API-DMAC7.html) 2004-12-31
ID27838A (id) 2001-04-26
HUP0103512A2 (hu) 2002-02-28
HRP20010200A2 (en) 2002-04-30
MA26689A1 (fr) 2004-12-20
NO319781B1 (no) 2005-09-12
BR9913855A (pt) 2001-07-24
BG65101B1 (bg) 2007-02-28
SK3532001A3 (en) 2001-12-03
TNSN99170A1 (fr) 2005-11-10
NZ509837A (en) 2002-11-26
PA8481201A1 (es) 2000-09-29
HK1039938A1 (zh) 2002-05-17
PT1114032E (pt) 2004-09-30
JP3561474B2 (ja) 2004-09-02
PE20001054A1 (es) 2000-10-14
CN1515259A (zh) 2004-07-28
EP1114032B1 (en) 2004-06-02
DZ2891A1 (fr) 2003-12-15
EA005761B1 (ru) 2005-06-30
CA2344248C (en) 2007-01-09
KR20010085814A (ko) 2001-09-07
CU23053A3 (es) 2005-06-24
CN1318057A (zh) 2001-10-17
PL346830A1 (en) 2002-02-25
EE200100167A (et) 2002-06-17
HRP20010200B1 (en) 2006-10-31
US6140343A (en) 2000-10-31
AR030523A1 (es) 2003-08-27
YU18101A (sh) 2004-05-12
DK1114032T3 (da) 2004-08-16
WO2000017165A1 (en) 2000-03-30
PL198124B1 (pl) 2008-05-30
GC0000108A (en) 2005-06-29
IS5858A (is) 2001-02-23
JP2002526476A (ja) 2002-08-20
EP1114032A1 (en) 2001-07-11
MY121405A (en) 2006-01-28
AU747715B2 (en) 2002-05-23
AP2001002100A0 (en) 2001-03-31
US6489478B1 (en) 2002-12-03
AU5440399A (en) 2000-04-10
ZA200101745B (en) 2002-05-02
DE69917790D1 (de) 2004-07-08
CZ2001954A3 (cs) 2001-12-12
ATE268324T1 (de) 2004-06-15
AP1345A (en) 2004-12-15
UA70960C2 (uk) 2004-11-15
CR6306A (es) 2003-08-28
HUP0103512A3 (en) 2002-03-28
GEP20032973B (en) 2003-05-27
SV1999000150A (es) 2000-06-06
TW502022B (en) 2002-09-11
BG105429A (en) 2001-12-29
NO20011349L (no) 2001-05-14
CA2344248A1 (en) 2000-03-30
ES2221420T3 (es) 2004-12-16
NO20011349D0 (no) 2001-03-16
EA200100249A1 (ru) 2001-08-27
DE69917790T2 (de) 2005-06-09
TR200100780T2 (tr) 2001-07-23
IL141388A0 (en) 2002-03-10
CO5290250A1 (es) 2003-06-27
GT199900147A (es) 1999-09-06

Similar Documents

Publication Publication Date Title
KR100428330B1 (ko) Cetp 저해제로서 4-카복시아미노-2-치환된-1,2,3,4-테트라하이드로퀴놀린
EP1114032B1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
EP0992496B1 (en) Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors
JP3655193B2 (ja) Ｃｅｔｐ阻害剤としての４−カルボキシアミノ−２−メチル−１，２，３，４−テトラヒドロキノリン類
AU775607B2 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CETP inhibitors
EP1607389A1 (en) 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors
MXPA99008586A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines in ani
MXPA01002759A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
MXPA01002880A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20080110

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090228

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000